oncogenes

Summary

Summary: Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.

Top Publications

  1. ncbi Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy
    I Bernard Weinstein
    College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Nat Clin Pract Oncol 3:448-57. 2006
  2. ncbi microRNAs as oncogenes and tumor suppressors
    Baohong Zhang
    Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, TX 79409 1163, USA
    Dev Biol 302:1-12. 2007
  3. pmc Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells
    Christine Mayr
    Howard Hughes Medical Institute, USA
    Cell 138:673-84. 2009
  4. ncbi A microRNA polycistron as a potential human oncogene
    Lin He
    Cold Spring Harbor Laboratory, Watson School of Biological Sciences, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
    Nature 435:828-33. 2005
  5. ncbi The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes
    Arnold J Levine
    Institute for Advanced Study, Princeton, NJ 08540, USA
    Science 330:1340-4. 2010
  6. pmc Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice
    Dinorah Friedmann-Morvinski
    Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
    Science 338:1080-4. 2012
  7. ncbi Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
    Jirina Bartkova
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, DK 2100 Copenhagen, Denmark
    Nature 444:633-7. 2006
  8. ncbi DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    Jirina Bartkova
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Nature 434:864-70. 2005
  9. ncbi Cancer genes and the pathways they control
    Bert Vogelstein
    Howard Hughes Medical Institute and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University Medical Institutions, Baltimore, Maryland 21231, USA
    Nat Med 10:789-99. 2004
  10. ncbi MicroRNAs as oncogenes and tumor suppressors
    Chang Zheng Chen
    Department of Microbiology and Immunology, Baxter Laboratory of Genetic Pharmacology, Institute for Cancer Stem Cell Biology and Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:1768-71. 2005

Research Grants

  1. NIH Director's Pioneer Award
    Junying Yuan; Fiscal Year: 2009
  2. Role of the Y-Located TSPY Gene in Human Oncogenesis
    Yun Fai Chris Lau; Fiscal Year: 2013
  3. FASEB SRC on Lysophospholipd Mediators in Health and Disease
    Julie D Saba; Fiscal Year: 2011
  4. Lung Lysyl Oxidase Regulation by Metal Ion Homeostasis
    Wande Li; Fiscal Year: 2013
  5. Role of Polyamines in MYCN-Amplified Neuroblastoma
    ANDRE BACHMANN; Fiscal Year: 2009
  6. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
  7. Genistein, microRNAs and kidney cancer
    Rajvir Dahiya; Fiscal Year: 2013
  8. BIOCHEMISTRY OF PRE-MRNA SPLICING
    Adrian R Krainer; Fiscal Year: 2010
  9. Molecular Regulation of Progesterone Synthesis
    John S Davis; Fiscal Year: 2013
  10. FOXP3-microRNA146-NFkB Axis in Tumor Suppression
    Lizhong Wang; Fiscal Year: 2013

Detail Information

Publications334 found, 100 shown here

  1. ncbi Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy
    I Bernard Weinstein
    College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Nat Clin Pract Oncol 3:448-57. 2006
    ..e. the 'Achilles' heel,' in specific cancers. Finally, we discuss the use of molecular targeted agents in combination with other anticancer agents as a strategy to optimize therapy and prevent disease recurrence...
  2. ncbi microRNAs as oncogenes and tumor suppressors
    Baohong Zhang
    Department of Environmental Toxicology, The Institute of Environmental and Human Health, Texas Tech University, Lubbock, TX 79409 1163, USA
    Dev Biol 302:1-12. 2007
    ..In addition, some miRNAs may function as oncogenes or tumor suppressors...
  3. pmc Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells
    Christine Mayr
    Howard Hughes Medical Institute, USA
    Cell 138:673-84. 2009
    In cancer cells, genetic alterations can activate proto-oncogenes, thereby contributing to tumorigenesis. However, the protein products of oncogenes are sometimes overexpressed without alteration of the proto-oncogene...
  4. ncbi A microRNA polycistron as a potential human oncogene
    Lin He
    Cold Spring Harbor Laboratory, Watson School of Biological Sciences, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
    Nature 435:828-33. 2005
    ..Together, these studies indicate that non-coding RNAs, specifically microRNAs, can modulate tumour formation, and implicate the mir-17-92 cluster as a potential human oncogene...
  5. ncbi The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes
    Arnold J Levine
    Institute for Advanced Study, Princeton, NJ 08540, USA
    Science 330:1340-4. 2010
    ..switch places the emphasis on producing intermediates for cell growth and division, and it is regulated by both oncogenes and tumor suppressor genes in a number of key cancer-producing pathways...
  6. pmc Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice
    Dinorah Friedmann-Morvinski
    Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA
    Science 338:1080-4. 2012
    ....
  7. ncbi Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
    Jirina Bartkova
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, DK 2100 Copenhagen, Denmark
    Nature 444:633-7. 2006
    ..Thus, senescence in human preneoplastic lesions is a manifestation of oncogene-induced DNA replication stress and, together with apoptosis, provides a barrier to malignant progression...
  8. ncbi DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
    Jirina Bartkova
    Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Nature 434:864-70. 2005
    ..Similar checkpoint responses were induced in cultured cells upon expression of different oncogenes that deregulate DNA replication...
  9. ncbi Cancer genes and the pathways they control
    Bert Vogelstein
    Howard Hughes Medical Institute and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University Medical Institutions, Baltimore, Maryland 21231, USA
    Nat Med 10:789-99. 2004
    ..The purposes of this review are to highlight examples of progress in these areas, indicate where knowledge is scarce and point out fertile grounds for future investigation...
  10. ncbi MicroRNAs as oncogenes and tumor suppressors
    Chang Zheng Chen
    Department of Microbiology and Immunology, Baxter Laboratory of Genetic Pharmacology, Institute for Cancer Stem Cell Biology and Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:1768-71. 2005
  11. ncbi A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors
    P Mathijs Voorhoeve
    Division of Tumour Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cell 124:1169-81. 2006
    ..In a screen for miRNAs that cooperate with oncogenes in cellular transformation, we identified miR-372 and miR-373, each permitting proliferation and tumorigenesis ..
  12. pmc MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes
    Yunqing Li
    Departments of Microbiology, Neurology and Pathology, University of Virginia, Charlottesville, VA 22908, USA
    Cancer Res 69:7569-76. 2009
    ..They show that miR-34a suppresses brain tumor growth by targeting c-Met and Notch. The results also suggest that miR-34a could serve as a potential therapeutic agent for brain tumors...
  13. pmc Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
    Lars Zender
    Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
    Cell 125:1253-67. 2006
    ..analyses delineated cIAP1, a known inhibitor of apoptosis, and Yap, a transcription factor, as candidate oncogenes in the amplicon...
  14. pmc Tumor suppressors and cell metabolism: a recipe for cancer growth
    Russell G Jones
    Rosalind and Morris Goodman Cancer Centre, McGill University, Montreal, Quebec, H3A 1A3, Canada
    Genes Dev 23:537-48. 2009
    ..In this review, we consider the potential role of tumor suppressors as metabolic regulators...
  15. ncbi Characterization of microRNA expression levels and their biological correlates in human cancer cell lines
    Arti Gaur
    Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire 03755, USA
    Cancer Res 67:2456-68. 2007
    ..of the NCI-60 cell lines, and we developed evidence for the identification of specific microRNAs as candidate oncogenes and tumor suppressor genes in different tumor types...
  16. ncbi A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes
    O A Kent
    The McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Oncogene 25:6188-96. 2006
    The known classes of genes that function as tumor suppressors and oncogenes have recently been expanded to include the microRNA (miRNA) family of regulatory molecules...
  17. ncbi Cancer. Addiction to oncogenes--the Achilles heal of cancer
    I Bernard Weinstein
    Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    Science 297:63-4. 2002
  18. pmc New targetable oncogenes in non-small-cell lung cancer
    Geoffrey R Oxnard
    Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02215, USA
    J Clin Oncol 31:1097-104. 2013
    ..lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying additional targetable oncogenes in non-small-cell lung cancer...
  19. pmc SOX2 gene regulates the transcriptional network of oncogenes and affects tumorigenesis of human lung cancer cells
    Si Chen
    School of Medicine, Nankai University, Tianjin, China
    PLoS ONE 7:e36326. 2012
    ..In addition, obviously higher expression of oncogenes c-MYC, WNT1, WNT2, and NOTCH1 was detected in side population (SP) cells than in non-side population (NSP) cells ..
  20. ncbi Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
    Harith Rajagopalan
    Sidney Kimmel Comprehensive Cancer Centre, Howard Hughes Medical Institution and Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Nature 418:934. 2002
    ....
  21. doi Oncogenes and cancer
    Carlo M Croce
    Department of Molecular Virology, Immunology, and Medical Genetics and the Human Cancer Genetics Program, Ohio State University Medical Center, Columbus, OH 43210, USA
    N Engl J Med 358:502-11. 2008
  22. pmc A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas
    Kartik M Mani
    Department of Biomedical Informatics DBMI, Columbia University, New York, NY 10032, USA
    Mol Syst Biol 4:169. 2008
    ..The method consistently ranked the known gene in the top 20 (0.3%), outperforming conventional approaches in 3 of 4 cases...
  23. pmc Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation
    Christine Mayr
    Howard Hughes Medical Institute and Department of Biology, Massachusetts Institute of Technology, and Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
    Science 315:1576-9. 2007
    ..Thus, losing miRNA-directed repression of an oncogene provides a mechanism for tumorigenesis, and disrupting a single miRNA-target interaction can produce an observable phenotype in mammalian cells...
  24. ncbi Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
    Levi A Garraway
    Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 436:117-22. 2005
    ..Together, these data suggest that MITF represents a distinct class of 'lineage survival' or 'lineage addiction' oncogenes required for both tissue-specific cancer development and tumour progression.
  25. ncbi Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Andrea H Bild
    Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    Nature 439:353-7. 2006
    ..Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics...
  26. pmc The tumor suppressor microRNA let-7 represses the HMGA2 oncogene
    Yong Sun Lee
    Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia 22908, USA
    Genes Dev 21:1025-30. 2007
    ....
  27. pmc Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer
    Kazimierz O Wrzeszczynski
    Bioinformatics and Genomics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States of America
    PLoS ONE 6:e28503. 2011
    ..interested in copy number variation as our base genomic property in the prediction of tumor suppressors and oncogenes in the altered ovarian tumor...
  28. ncbi Oncogene addiction
    I Bernard Weinstein
    Herbert Irving Comprehensive Cancer Center, Department of Medicine, Columbia University Medical Center, New York, New York 10032 2704, USA
    Cancer Res 68:3077-80; discussion 3080. 2008
    ..e., the "Achilles heel") in specific cancers. Combination therapy may also be required to prevent the escape of cancers from a given state of oncogene addiction...
  29. pmc Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer
    Raffaella Di Micco
    IFOM Foundation FIRC Institute of Molecular Oncology Foundation, Milan, Italy
    Nat Cell Biol 13:292-302. 2011
    ..These results indicate that heterochromatin induced by oncogenic stress restrains DDR and suggest that the use of chromatin-modifying drugs in cancer therapies may benefit from the study of chromatin and DDR status of tumours...
  30. ncbi Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    Paul T C Wan
    Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK
    Cell 116:855-67. 2004
    ..The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism...
  31. ncbi Molecular classification of cancer: class discovery and class prediction by gene expression monitoring
    T R Golub
    Whitehead Institute Massachusetts Institute of Technology Center for Genome Research, Cambridge, MA 02139, USA
    Science 286:531-7. 1999
    ....
  32. ncbi Gene amplification in cancer
    Donna G Albertson
    Cancer Research Institute and Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Trends Genet 22:447-55. 2006
    ..Clinically, amplification has prognostic and diagnostic usefulness, and is a mechanism of acquired drug resistance...
  33. ncbi An oncogene-induced DNA damage model for cancer development
    Thanos D Halazonetis
    Department of Molecular Biology and Department of Biochemistry, University of Geneva, CH 1205 Geneva, Switzerland
    Science 319:1352-5. 2008
    ..Yet recent experimental findings suggest that, in both precancerous lesions and cancers, activated oncogenes induce stalling and collapse of DNA replication forks, which in turn leads to formation of DNA DSBs...
  34. ncbi Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
    W J Muller
    Harvard Medical School Department of Genetics, Boston, Massachusetts 02115
    Cell 54:105-15. 1988
    ..stochastic occurrence of solitary mammary tumors in transgenic mice bearing the MMTV/c-myc or the MMTV/v-Ha-ras oncogenes, transgenic mice uniformly expressing the MMTV/c-neu gene develop mammary adenocarcinomas that involve the ..
  35. ncbi High-throughput oncogene mutation profiling in human cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 39:347-51. 2007
    ..This approach established robust mutation distributions spanning 17 cancer types. Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation...
  36. pmc A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations
    Tao Xie
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
    PLoS ONE 7:e42001. 2012
    ..1 was identified (p<0.01). Focal aberrations identified by the GISTIC method confirmed amplifications of oncogenes including EGFR, ERBB2, CCND1, MET, and MYC, and deletions of tumor suppressors including TP53, APC, and SMAD4, ..
  37. ncbi miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells
    Giorgio Zauli
    Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy
    Clin Cancer Res 17:2712-24. 2011
    To elucidate new molecular mechanisms able to downregulate the mRNA levels of key oncogenes, such as B-Myb and E2F1, in a therapeutic perspective.
  38. pmc The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence
    Lixin Hong
    Key Laboratory of the Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University, Xiamen, Fujian, China
    Cancer Res 70:8547-57. 2010
    In mammalian cells, activation of oncogenes usually triggers innate tumor-suppressing defense mechanisms, including apoptosis and senescence, which are compromised by additional mutations before cancers are developed...
  39. pmc High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
    Edwin Choy
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 118:2905-14. 2012
    ..The identification of new genes that are mutated in osteosarcomas is critical to developing a better understanding of the molecular pathogenesis of this disease and discovering new targets for therapeutic development...
  40. pmc Molecular cytogenetic analysis of 11 new breast cancer cell lines
    F Forozan
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892 4470, USA
    Br J Cancer 81:1328-34. 1999
    ..One-third of these loci affected breast cancer oncogenes, whose amplifications were validated with specific probes: 17q12 (two cell lines with ERBB2 amplifications), ..
  41. ncbi Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes
    A Ullrich
    Nature 313:756-61. 1985
    ..There are sequence homologies to human epidermal growth factor receptor and the members of the src family of oncogene products...
  42. ncbi p53: guardian of the genome and policeman of the oncogenes
    Alejo Efeyan
    Tumor Suppression Group, Spanish National Cancer Research Center CNIO, Madrid, Spain
    Cell Cycle 6:1006-10. 2007
    ..consists in sensing and reacting to DNA damage through the ATM/ATR and Chk1/Chk2 kinases, and "policeman of the oncogenes" that, correspondingly, consists in responding to oncogenic signaling through the p53-stabilizing protein ARF...
  43. ncbi Two G protein oncogenes in human endocrine tumors
    J Lyons
    Department of Human Genetics, Cetus Corporation, Emeryville CA 94608
    Science 249:655-9. 1990
    ..These findings suggest that human tumors may harbor oncogenic mutations in various G protein alpha chain genes...
  44. pmc Oncogenes induce genotoxic stress by mitotic processing of unusual replication intermediates
    Kai J Neelsen
    Institute of Molecular Cancer Research, University of Zurich, CH 8057 Zurich, Switzerland
    J Cell Biol 200:699-708. 2013
    ..We propose that nucleolytic processing of unusual replication intermediates mediates oncogene-induced genotoxicity and that limiting such processing to mitosis is a central anti-tumorigenic function of the DNA damage checkpoints...
  45. ncbi Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia
    Irene Homminga
    Department of Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Cancer Cell 19:484-97. 2011
    ..Two T-ALL subtypes were identified that lacked rearrangements of known oncogenes. One subtype associated with cortical arrest, expression of cell cycle genes, and ectopic NKX2-1 or NKX2-2 ..
  46. pmc Proinvasion metastasis drivers in early-stage melanoma are oncogenes
    Kenneth L Scott
    Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 20:92-103. 2011
    ..Furthermore, we show that one such gene, ACP5, confers spontaneous metastasis in vivo, engages a key pathway governing metastasis, and is prognostic in human primary melanomas...
  47. pmc Oncogenes and tumor suppressor genes
    Eva Y H P Lee
    Department of Biological Chemistry and Department of Developmental and Cell Biology, University of California, Irvine, California 92697 4037, USA
    Cold Spring Harb Perspect Biol 2:a003236. 2010
    Breast cancer progression involves multiple genetic events, which can activate dominant-acting oncogenes and disrupt the function of specific tumor suppressor genes...
  48. pmc Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors
    Bruno K Robbs
    Division of Cellular Biology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
    Mol Cell Biol 28:7168-81. 2008
    ..These results suggest that the NFAT1 gene acts as a tumor suppressor gene and the NFAT2 short isoform acts gene as an oncogene, supporting different roles for the two transcription factors in tumor development...
  49. ncbi Control of autophagy by oncogenes and tumor suppressor genes
    M C Maiuri
    INSERM, U848, Apoptosis Cancer and Immunity, F 94805 Villejuif, France
    Cell Death Differ 16:87-93. 2009
    Multiple oncogenes (in particular phosphatidylinositol 3-kinase, PI3K; activated Akt1; antiapoptotic proteins from the Bcl-2 family) inhibit autophagy...
  50. ncbi Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
    E Shtivelman
    Nature 315:550-4. 1985
    ..Characterization of an 8-kilobase RNA specific to chronic myelogenous leukaemia shows it to be a fused transcript of the two genes. The fused protein that would be produced is probably involved in the malignant process...
  51. ncbi Chromosome aberrations in solid tumors
    Donna G Albertson
    Cancer Research Institute, University of California San Francisco, San Francisco, California 94143 0808, USA
    Nat Genet 34:369-76. 2003
    ....
  52. ncbi Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines
    Z Q Yang
    Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, Japan
    Cancer Res 60:4735-9. 2000
    ..Because amplified regions often harbor oncogenes and/or other tumor-associated genes, and because 9p23-24 amplification had been reported in various other types ..
  53. pmc Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer
    Min Zhao
    Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    PLoS ONE 7:e44175. 2012
    So far, investigators have found numerous tumor suppressor genes (TSGs) and oncogenes (OCGs) that control cell proliferation and apoptosis during cancer development...
  54. ncbi Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes
    S A McCarthy
    DNAX Research Institute, Palo Alto, California 94304, USA
    Genes Dev 9:1953-64. 1995
    ....
  55. ncbi Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis
    Moritz Bennecke
    2nd Department of Medicine, Klinikum rechts der Isar, Technical University Munich, Germany
    Cancer Cell 18:135-46. 2010
    ....
  56. pmc Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes
    E Hu
    Dana Farber Cancer Institute, Boston, MA 02115
    EMBO J 13:3094-103. 1994
    ..mRNA for the metalloproteases stromelysin (MMP-3) and type I collagenase (MMP-1), which are often induced by oncogenes and growth factors and have been implicated in tumor invasiveness, cannot be induced by epidermal growth factor ..
  57. pmc Genome-wide screening for genetic alterations in esophageal cancer by aCGH identifies 11q13 amplification oncogenes associated with nodal metastasis
    Jianming Ying
    Department of Pathology, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
    PLoS ONE 7:e39797. 2012
    ..Chromosomal abnormalities, such as recurrent amplifications and homozygous deletions, directly contribute to tumorigenesis through altering the expression of key oncogenes and tumor suppressor genes.
  58. ncbi 14-3-3 proteins as potential oncogenes
    Guri Tzivion
    Karmanos Cancer Institute and Department of Pathology, Wayne State University, Detroit, MI 48201, USA
    Semin Cancer Biol 16:203-13. 2006
    ..Importantly, the involvement of 14-3-3 proteins in the regulation of various oncogenes and tumor suppressor genes points to a potential role in human cancer...
  59. pmc Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes
    Gwyndolen C Harburg
    Department of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, CA 95064, USA
    J Mammary Gland Biol Neoplasia 16:257-70. 2011
    ..during tumorigenesis and tumor progression suggests that AGMs also play a crucial role as tumor suppressors and oncogenes in breast cancer...
  60. pmc Oncogenic H-Ras V12 promotes anchorage-independent cytokinesis in human fibroblasts
    Minna Thullberg
    Department of Biosciences and Nutrition, Karolinska Institutet, SE 141 57 Huddinge, Sweden
    Proc Natl Acad Sci U S A 104:20338-43. 2007
    ..required for cell proliferation of untransformed cells, whereas anchorage-independent growth can be induced by oncogenes and is a hallmark of transformation...
  61. pmc Identification of novel candidate oncogenes in chromosome region 17p11.2-p12 in human osteosarcoma
    Joeri Both
    Department of Genome Analysis, Academic Medical Center, Amsterdam, The Netherlands
    PLoS ONE 7:e30907. 2012
    ..2-p12 is amplified in about 25% of cases. In previous studies, COPS3 and PMP22 have been identified as candidate oncogenes in this region...
  62. pmc Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3
    M Chesi
    Genetics Department, National Cancer Institute, Bethesda, Maryland 20889 5105, USA
    Nat Genet 16:260-4. 1997
    Dysregulation of oncogenes by translocation to the IgH locus (14q32) is a seminal event in the pathogenesis of B-cell tumours. In multiple myeloma (MM), translocations to the IgH locus have been reported at an incidence of 20-60%...
  63. pmc Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas
    A L Feldman
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:574-80. 2009
    b>Oncogenes involved in recurrent chromosomal translocations serve as diagnostic markers and therapeutic targets in hematopoietic tumors...
  64. ncbi Polarity proteins in migration and invasion
    S Etienne-Manneville
    Cell Polarity and Migration Group, Institut Pasteur and CNRS URA 2582, Paris Cedex 15, France
    Oncogene 27:6970-80. 2008
    ..The aim of this review is to highlight the molecular relationship between the control of cell polarity and the regulation of cell motility during oncogenesis...
  65. pmc Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways
    S Song
    McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, 1400 University Avenue, Madison, WI 53706, USA
    Proc Natl Acad Sci U S A 95:2290-5. 1998
    ..Thus pRb and/or pRb-like proteins likely mediate both p53-dependent and p53-independent responses to radiation...
  66. ncbi MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity?
    P Mathijs Voorhoeve
    Cancer and Stem Cell Biology Program, Duke NUS Graduate Medical School, 8 College Road, Singapore
    Biochim Biophys Acta 1805:72-86. 2010
    ..of tumor origin and behavior, they are causally linked to the emergence and development of cancer by acting as oncogenes or tumor suppressors...
  67. pmc In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML
    Anmaar M Abdul-Nabi
    Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS ONE 5:e12464. 2010
    Different fusion oncogenes in acute myeloid leukemia (AML) have distinct clinical and laboratory features suggesting different modes of malignant transformation...
  68. ncbi Traps to catch unwary oncogenes
    A O Hueber
    Biochemistry of the Cell Nucleus Laboratory, Imperial Cancer Research Fund, London, UK
    Trends Genet 14:364-7. 1998
    ..We discuss such synergy with respect to the cooperating oncogenes MYC, RAS and BCL2.
  69. ncbi CDC6: from DNA replication to cell cycle checkpoints and oncogenesis
    Luis R Borlado
    DNA replication Group, Molecular Oncology Programme, Spanish National Cancer Research Centre, Melchor Fernandez Almagro 3, E 28029 Madrid, Spain
    Carcinogenesis 29:237-43. 2008
    ..These findings indicate that deregulation of CDC6 expression in human cells poses a serious risk of carcinogenesis...
  70. pmc Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma
    A J Crew
    Section of Molecular Carcinogenesis, Haddow Laboratories, Belmont, Sutton, Surrey
    EMBO J 14:2333-40. 1995
    ..Sequence analysis has demonstrated heterogeneity in the fusion transcripts with the formation of two distinct SYT-SSX1 fusion junctions and two distinct SYT-SSX2 fusion junctions...
  71. pmc Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes
    M Nees
    Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, Bethesda, Maryland, USA
    J Virol 75:4283-96. 2001
    ..Thus, high-level expression of the HPV-16 E6 protein in differentiating keratinocytes directly alters expression of genes that influence host resistance to infection and immune function...
  72. pmc Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR
    David W Schoppy
    Abramson Family Cancer Research Institute and Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6160, USA
    J Clin Invest 122:241-52. 2012
    ....
  73. pmc Mapping of the p53 and mdm-2 interaction domains
    J Chen
    Department of Molecular Biology, Princeton University, New Jersey 08544 1014
    Mol Cell Biol 13:4107-14. 1993
    ..This region contains the transactivation domain of p53, suggesting that mdm-2 may inhibit p53 function by disrupting its interaction with the general transcription machinery...
  74. ncbi Molecular genetics of small cell lung carcinoma
    I I Wistuba
    Department of Anatomic Pathology, P. Universidad Catolica de Chile, Santiago, Chile
    Semin Oncol 28:3-13. 2001
    ..Dominant oncogenes of the Myc family are frequently overexpressed in both SCLC and non-small cell lung cancer (NSCLC), while the K-..
  75. pmc miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
    Alexander Swarbrick
    Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
    Nat Med 16:1134-40. 2010
    ..We demonstrate a new mechanism of p53 regulation in cancer and stem cells and uncover a potential therapeutic target for neuroblastoma...
  76. pmc "Hit-and-run" transformation by adenovirus oncogenes
    M Nevels
    , , D-93053 Regensburg, Germany
    J Virol 75:3089-94. 2001
    According to classical concepts of viral oncogenesis, the persistence of virus-specific oncogenes is required to maintain the transformed cellular phenotype...
  77. pmc Multiple stress signals activate mutant p53 in vivo
    Young Ah Suh
    Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 71:7168-75. 2011
    ..In this report, we examined the role of oncogenes, DNA damage, and reactive oxygen species, signals that stabilize wild-type p53, on the stabilization of mutant ..
  78. ncbi Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer
    Eija H Mahlamäki
    Laboratory of Cancer Genetics, Tampere University Hospital and University of Tampere, Tampere, Finland
    Genes Chromosomes Cancer 35:353-8. 2002
    ..These results illustrate that amplification of genes from the 8q, 11q, 17q, and 20q chromosome arms is common in pancreatic cancer...
  79. ncbi Oncogenes in melanoma
    David Polsky
    Department of Dermatology, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA
    Oncogene 22:3087-91. 2003
    ..We provide a general overview of the mechanisms of oncogene activation and the functions of oncogenes. Lastly, we review oncogenic events in melanoma.
  80. ncbi Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus
    M D Waterfield
    Nature 304:35-9. 1983
    ..This similarity suggests a mechanism for transformation by SSV and other agents, involving expression of growth factors...
  81. ncbi Modeling liver cancer using zebrafish: a comparative oncogenomics approach
    Siew Hong Lam
    Department of Biological Sciences, National University of Singapore, Singapore
    Cell Cycle 5:573-7. 2006
    ..In addition, our comparative oncogenomic work provides a general framework for comparing and validating microarray data of zebrafish model with human cancer, thus adding confidence of using the zebrafish to model human cancers...
  82. ncbi Cancer-associated IDH mutations: biomarker and therapeutic opportunities
    K E Yen
    Molecular Oncology, Agios Pharmaceuticals, Cambridge, MA 02139, USA
    Oncogene 29:6409-17. 2010
    ..Several hypotheses implicating the elevated levels of D-2HG and tumorigenesis, and the therapeutic potential of targeting mutant IDH enzymes will be discussed...
  83. pmc The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13
    T Boehm
    Medical Research Council Laboratory of Molecular Biology, Cambridge United Kingdom
    Proc Natl Acad Sci U S A 88:4367-71. 1991
    ..The results define the rhombotin gene family as a class of T-cell oncogenes with duplicated cysteine-rich LIM domains.
  84. ncbi Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
    Scott A Tomlins
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 448:595-9. 2007
    ..Identification of distinct classes of ETS gene rearrangements demonstrates that dormant oncogenes can be activated in prostate cancer by juxtaposition to tissue-specific or ubiquitously active genomic loci...
  85. ncbi Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: the architecture of a transduced oncogene
    K H Klempnauer
    Cell 31:453-63. 1982
    ..Comparisons between the sequences of v-myb and c-myb indicate that transduction of c-myb to form v-myb probably resulted from an initial DNA rearrangement and the subsequent use of a spliced RNA as an intermediate...
  86. pmc Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia
    Karen Keeshan
    Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Cell 10:401-11. 2006
    ..Furthermore, Trib2 expression was elevated in a subset of human AML patient samples. Together, our data identify Trib2 as an oncogene that induces AML through a mechanism involving inactivation of C/EBPalpha...
  87. ncbi Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes
    Cathy B Moelans
    Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands
    Mod Pathol 23:1029-39. 2010
    Several oncogenes and tumor-suppressor genes have been shown to be implicated in the development, progression and response to therapy of invasive breast cancer...
  88. pmc Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal
    Rocio Sotillo
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 464:436-40. 2010
    ..This has led to the search for compounds that specifically target and inhibit oncogenes as anticancer agents...
  89. pmc The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL
    Weimin Ci
    Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Blood 113:5536-48. 2009
    ..The specific BCL6 inhibitor retro-inverso BCL6 peptidomimetic inhibitor-induced expression of BCL2 and other oncogenes, consistent with direct repression effects by BCL6...
  90. pmc Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases
    Yihua Sun
    Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
    J Clin Oncol 28:4616-20. 2010
    ..To determine the proportion of lung adenocarcinomas from East Asian never-smokers who harbor known oncogenic driver mutations...
  91. pmc Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer
    K A Kwei
    Department of Pathology, Stanford University, Stanford, CA 94305 5176, USA
    Oncogene 27:3635-40. 2008
    Lung cancer is a leading cause of cancer death, where the amplification of oncogenes contributes to tumorigenesis. Genomic profiling of 128 lung cancer cell lines and tumors revealed frequent focal DNA amplification at cytoband 14q13...
  92. ncbi Many roads lead to oncogene-induced senescence
    S Courtois-Cox
    Genetics Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 2115, USA
    Oncogene 27:2801-9. 2008
    ..This review will focus on integrating current models and will highlight data that provide new insight into the signals that function to suppress human tumor development...
  93. ncbi DAPk protein family and cancer
    Devrim Gozuacik
    Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
    Autophagy 2:74-9. 2006
    ..autophagic cell death signals in response to various cellular stresses including the misregulated expression of oncogenes in pre-malignant cells...
  94. ncbi Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia
    Severine Landais
    Laboratoire de Biologie Moleculaire, Departement des Sciences Biologiques, Universite du Quebec a Montreal, Montreal, Quebec, Canada
    Cancer Res 67:5699-707. 2007
    ....
  95. ncbi Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma
    Maaike van Dartel
    Department of Human Genetics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands
    Cancer Genet Cytogenet 139:91-6. 2002
    ..p12 has been found in 13%-29% of high-grade osteosarcomas, suggesting the presence of an oncogene or oncogenes that may contribute to their development...
  96. ncbi Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications
    Cynthia Osborne
    University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390 8852, USA
    Oncologist 9:361-77. 2004
    ..b>Oncogenes refer to those genes whose alterations cause gain-of-function effects, while tumor suppressor genes cause loss-..
  97. ncbi Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor
    R F Doolittle
    Science 221:275-7. 1983
    ..The mechanism by which v-sis transforms cells could involve the constitutive expression of a protein with functions similar or identical to those of a factor active transiently during normal cell growth...
  98. ncbi Spi-1 is a putative oncogene in virally induced murine erythroleukaemias
    F Moreau-Gachelin
    INSERM U 248, Faculte de Medecine Lariboisiere Saint Louis, Paris, France
    Nature 331:277-80. 1988
    ..insertional mutagenesis has been proposed as an efficient mechanism to turn on or to increase the expression of oncogenes in several avian or mammal models...
  99. pmc Genistein suppresses prostate cancer growth through inhibition of oncogenic microRNA-151
    Takeshi Chiyomaru
    Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e43812. 2012
    ..This study suggests that genistein mediated suppression of oncogenic miRNAs can be an important dietary therapeutic strategy for the treatment of PCa...
  100. pmc Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma
    Xuan Bich Trinh
    Translational Cancer Research Unit, St Augustinus GZA Hospitals, Antwerp, Belgium
    PLoS ONE 6:e22469. 2011
    ..The identification of specific targets for treatment of ovarian cancer patients remains a challenge. The objective of this study is the analysis of oncogenic pathways in ovarian cancer and their relation with clinical outcome...
  101. pmc MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors
    Long R Jiao
    Hepato Pancreato Biliary Surgical Unit, Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, London, UK
    PLoS ONE 7:e32068. 2012
    ..The mechanistic consequences of miRNA dysregulation were further evaluated...

Research Grants71

  1. NIH Director's Pioneer Award
    Junying Yuan; Fiscal Year: 2009
    ..No Abstract provided ..
  2. Role of the Y-Located TSPY Gene in Human Oncogenesis
    Yun Fai Chris Lau; Fiscal Year: 2013
    ..This project will shed important insights on how the Y-oncogene and X-tumor suppressor operate and how one can interfere or boost their actions respectively to treat prostate cancer. ..
  3. FASEB SRC on Lysophospholipd Mediators in Health and Disease
    Julie D Saba; Fiscal Year: 2011
    ..principal enzyme responsible for generating LPA) and sphingosine kinase 1 (which generates S1P) are bona fide oncogenes that promote transformation in model systems, are aberrantly expressed in many human cancers, and serve as ..
  4. Lung Lysyl Oxidase Regulation by Metal Ion Homeostasis
    Wande Li; Fiscal Year: 2013
    ..The outcomes of the proposed research are expected to enhance our understanding of mechanisms of LO gene silence by Cd providing the basis for developing prophylaxis and treatment strategies for Cd-related lung diseases. ..
  5. Role of Polyamines in MYCN-Amplified Neuroblastoma
    ANDRE BACHMANN; Fiscal Year: 2009
    ..Our research will be useful in the development of novel treatments for the most aggressive forms of the childhood cancer neuroblastoma. ..
  6. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  7. Genistein, microRNAs and kidney cancer
    Rajvir Dahiya; Fiscal Year: 2013
    ..The miRNA-mediated repression of oncogenes or activation of tumor suppressor genes will be analyzed by luciferase assays using 3'UTR or 5'UTR ..
  8. BIOCHEMISTRY OF PRE-MRNA SPLICING
    Adrian R Krainer; Fiscal Year: 2010
    ..The proposed studies are aimed at understanding basic cellular mechanisms of gene expression, and may provide the basis for developing or improving diagnostic tools and therapeutic agents for these diseases. ..
  9. Molecular Regulation of Progesterone Synthesis
    John S Davis; Fiscal Year: 2013
    ..Considering the importance sex steroids in health and disease, we must have a better understanding of the mechanisms controlling the synthesis of steroid hormones. ..
  10. FOXP3-microRNA146-NFkB Axis in Tumor Suppression
    Lizhong Wang; Fiscal Year: 2013
    ..FOXP3 directly targets critical oncogenes HER2/ErbB2 and SKP2 and a tumor suppressor gene p21...
  11. Bioassay for Breast Cancer Prevention
    JoEllen Welsh; Fiscal Year: 2010
    ....
  12. Molecular Mechanisms of Disease Progression in Myeloid Malignancy
    ELIZABETH ANN EKLUND; Fiscal Year: 2013
    ..Targeting these mechanisms may lead to cure in CML by abolishing the CSC/LSC, and suggest therapeutic approaches to other forms of cancer with dysregulation of Fas and bcatenin. ..
  13. Cellular and Animal Models of FUS Mutations in ALS
    Eric J Huang; Fiscal Year: 2013
    ..Once available, these models will serve as novel platforms to identify new therapeutic targets for diseases caused by FUS/TLS mutations. ..
  14. PTEN TUMOR SUPPRESSOR AND SIGNAL TRANSDUCTION
    RAMON E PARSONS; Fiscal Year: 2012
    ..09/04) Page 4 Form Page 3 ..
  15. Overcoming Temozolomide Resistance using MGMT-targeting Spherical Nucleic Acids
    TIMOTHY L SITA; Fiscal Year: 2013
    ..blood-brain barrier (BBB) and blood-tumor barrier (BTB), penetrate xenografted, intracranial tumors, silence GBM oncogenes, and increase survival in mice...
  16. CPG METHYLATION AND MUTATION
    Gerd P Pfeifer; Fiscal Year: 2013
    ..In parallel, we will study molecular pathways involving the Polycomb repression complex that might operate during tumor progression to promote hypermethylation of CpG islands in malignant tissue. ..
  17. Regulation of K-Ras by a Farnesyl-electrostatic Switch
    MARK REID PHILIPS; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Oncogenes are genes that cause cancer. K-Ras is the most important human oncogene...
  18. Molecular Mechanisms of Chemoprevention: NRF2 Signaling
    Thomas W Kensler; Fiscal Year: 2013
    ..We will also evaluate the predictive value of monitoring DNA circulating in plasma for mutations in target oncogenes using quantitative short oligonucleotide mass spectrometry...
  19. Interaction between RNA interference and RNA editing pathways
    Kazuko Nishikura; Fiscal Year: 2013
    ..Certain miRNAs can function as tumor suppressors and oncogenes. Thus, the current grant proposal to investigate the effect of A&I editing of miRNAs and siRNAs has ..
  20. The PKCepsilon-regulated oncogenic and tumor suppressor roles of ATF2 in melanoma
    ERIC KIRK LAU; Fiscal Year: 2013
    ..abstract_text> ..
  21. Roles of NF-kB/Rel in the pathogenesis of breast cancer
    Gail E Sonenshein; Fiscal Year: 2012
    ..on the roles of individual NF-?B complexes that are aberrantly activated by environmental carcinogens or oncogenes in promoting invasive breast cancer will be forthcoming;findings should be applicable to wide-spectrum of ..
  22. Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapy
    Bingliang Fang; Fiscal Year: 2013
    ..The goal of this proposal is to perform pre-clinical studies on their antitumor activities in lung cancer cells in vitro and in vivo that are required for future clinical trials. ..
  23. RADIATION-INDUCED THYROID CANCER
    Heinz Ulrich G Weier; Fiscal Year: 2011
    ..We expect this research to lead to improved control of PTC with regard to early disease detection and better disease management and, thus, to enhance public health services. ..
  24. Role of Matrix Metalloproteinase-1 in Endothelial Cell Senescence
    Catherine D Mao; Fiscal Year: 2010
    Premature cell senescence induced by oncogenes and oxidative stress in vitro recapitulates many facets of replicative senescence and in vivo cellular aging...
  25. Validation of microRNAs as therapeutic targets in hematological malignancies
    Natarajan Muthusamy; Fiscal Year: 2013
    ..Therefore, we propose here to replace the low levels of natural microRNAs in leukemia cells with synthetic microRNAs as novel therapeutic approach to leukemia patients. ..
  26. MicroRNAs in the Progression and Metastisis of Prostate Cancer
    Rajvir Dahiya; Fiscal Year: 2013
    ..we hypothesize that down-regulation of a set of microRNAs can inhibit tumor suppressor genes or activate oncogenes and re-expression of these miRNAs can reverse these effects thereby regulating prostate cancer progression...
  27. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline F Bromberg; Fiscal Year: 2010
    ....
  28. Lysosomal phospholipase A2 in autoimmune disease
    JAMES ALAN SHAYMAN; Fiscal Year: 2013
    ..Understanding the mechanisms whereby impaired degradation of phospholipids result in the autoimmune phenotype may provide new insights into the pathogenesis of lupus and potential new targets for therapy. ..
  29. Fnip1 Function in Lymphocyte Development, Activation and Metabolism
    Brian M Iritani; Fiscal Year: 2013
    ..abstract_text> ..
  30. Role of Heat Shock Transcription Factor Hsf1 in Tumorigenesis
    Nahid F Mivechi; Fiscal Year: 2013
    ..We will use a conditional gene knockout technology to examine the effects of hsf1 deficiency in the Her2/Neu-induced breast cancer model for tumors of epithelial origin. ..
  31. Integrative Pathway Analysis of Epigenomic/transcriptional Alteration in HNSCC
    Joseph A Califano; Fiscal Year: 2010
    ..that genome-wide epigenetic unmasking and promoter hypomethylation frequently activate candidate proto-oncogenes and tumor specific cancer testes antigens in head and neck squamous cell carcinoma (HNSCC)...
  32. Host Defense Mechanisms in Polyaromatic Hydrogen Carcinogenesis
    Craig A Elmets; Fiscal Year: 2013
    ..We have developed novel reagents and we utilize them as a vaccine to determine if they augment immunity to PAHs and can be used to prevent tumors from developing in the first place. ..
  33. Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia
    Andrew Napper; Fiscal Year: 2012
    ..The ultimate goal of this project is to discover targeted molecular therapies that treat these infant leukemias. ..
  34. Evaluation of novel FoxM1 inhibitors against liver cancer
    Andrei L Gartel; Fiscal Year: 2012
    ..Completion of our proposal will enable us to determine if thiazole antibiotics are suitable for further clinical development. ..
  35. Regulation of the VDJ recombinase during genotoxic stress
    Karla K Rodgers; Fiscal Year: 2013
    ..The ability to enhance such a regulatory process may lead to decreased risks of developing lymphoid malignancies following exposure to radiation and other DNA damaging drugs. ..
  36. Characterizing gene regulation with single molecule sensitive probes
    Philip J Santangelo; Fiscal Year: 2013
    ..or in upstream signaling pathways affect the stability and/or translational efficiency of mRNAs encoding proto-oncogenes, cytokines, cell cycle regulators and other regulatory proteins to promote tumorigenesis and cancer progression, ..
  37. Role of AIB1 in malignant progression
    Anna Tate Riegel; Fiscal Year: 2013
    ..Identification of novel pathways can be used to understand drivers of malignant progression and design novel therapeutic strategies. ..
  38. Effect of bisphenol A exposure on mammary stem cell function and transformation
    Luzhe Sun; Fiscal Year: 2013
    ..Furthermore, modulation of oncogenes and tumor suppressors has been shown to increase stem cell compartment and self-renewal function of MaSCs, ..
  39. Tunable Insulin Resistance in a Drosophila Model of Diabetes
    ELENA M GRACHEVA; Fiscal Year: 2010
    ..and created a cancer fly model where flies die during a discreet point in their development by over-expressing oncogenes providing a rescue-from-lethality screening readout...
  40. Chromatin regulation by human SIRT7 in aging-associated cellular programs
    Katrin F Chua; Fiscal Year: 2013
    ..Cellular senescence programs are triggered by telomere dysfunction, DNA damage, activated oncogenes, and other cellular stresses in the contexts of cancer and aging...
  41. Mitochondrial Metabolism and ROS Regulate Lung Cancer
    Navdeep S Chandel; Fiscal Year: 2013
    ....
  42. Detection of Prostate Cancer Genomic Signatures in Blood
    Amin I Kassis; Fiscal Year: 2010
    ..in tumor-bearing mice and in a few cancer patients fully support our expectations and show that (i) multiple oncogenes and tumor-specific genomic signatures are selectively acquired/expressed within phagocytic cells;(ii) these ..
  43. Nanotheranostics for Early Colorectal Cancer Detection and Treatment
    Jeffrey S Souris; Fiscal Year: 2013
    ..is postulated to arise via multiple independent pathways that include mutations and alterations in numerous oncogenes and tumor suppressor genes (e.g., APC gene inactivation, K-ras oncogene activation, and p53 mutation)...
  44. Ecd as a regulator of cell cycle and breast oncogenesis
    Vimla Band; Fiscal Year: 2013
    ..These features are reminiscent of senescence induced by oncogenes, such as Ras...
  45. Screen for Small Molecule Regulators of Retinal Progenitor Epithelial Cell Phagoc
    CHARLES YOON HYUNG CHO; Fiscal Year: 2010
    ..This proposal seeks to develop new assay technology that could test several hundred thousand compounds to speed the development of new treatments for this devastating disease. ..
  46. The role of the orphan receptor tyrosine kinase Ros1 in vascular disease
    ZIAD ANWAR ALI; Fiscal Year: 2011
    ..Thus, understanding how this receptor is activated and identifying the pathways that regulate its function may lead to new therapies for blood vessel disorders - currently the leading killer in the Western World. ..
  47. PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
    Irwin H Gelman; Fiscal Year: 2013
    ..kinase (PK) C has been considered cancer-promoting based on early data showing that phorbol esters could induce oncogenes is through the activation of so called classic and novel PKC isozymes...
  48. A Validated Resource of Thyroid Cancer Cell Lines for Pathway Discovery
    JEFFREY ALLEN KNAUF; Fiscal Year: 2010
    ..lines, gene expression platforms, mass spectrometry genotyping, CGH array analysis, mutational screen of key oncogenes and tumor suppressor genes and high throughput pathway activation analysis by Western blotting)...
  49. Role of Cited2 in Hematopoiesis
    Yu Chung Yang; Fiscal Year: 2011
    ....
  50. Roles of Hox genes in skin and hair follicle development
    Alexander Awgulewitsch; Fiscal Year: 2010
    ..Our goal is to determine how these genes interact with each other, which will ultimately define how these diseases can be approached therapeutically. ..
  51. IKKbeta:Bi-Functional Regulator of Hepatocyte Proliferation
    Hyam L Leffert; Fiscal Year: 2010
    ..Attenuated co-regulated expression of hepatocyte IKK[unreadable] and JNK2 may both facilitate hepatocyte proliferation and increase the susceptibility of hepatocytes to carcinogenesis. ..
  52. C MYC--TRANSCRIPTION AND APOPTOSIS
    Chi V Dang; Fiscal Year: 2011
    ....
  53. Aberrant activation of HGF/MET signaling as a therapeutic target in AML
    Alex Kentsis; Fiscal Year: 2013
    ..With the support provided by the K08 award, Dr. Kentsis'project will lead to the development of clinically effective HGF/MET targeted therapy for AML. ..
  54. MAMMALIAN POLYAMINE METABOLISM
    David J Feith; Fiscal Year: 2013
    ..The successful completion of these studies will lead to a more complete understanding of polyamine function in epithelial carcinogenesis and will enhance future development of polyamine-targeted therapies to prevent and treat cancer. ..
  55. Role of POZ-zinc finger proteins in tumorigenesis.
    Pier Paolo Pandolfi; Fiscal Year: 2013
    ..In view of the critical role exerted by this protein in tumorigenesis and embryonic development the further elucidation of POKEMON/LRF function and role in human cancer is of great relevance to biomedical research. ..
  56. Long-Range Genetic and Epigenetic Control of Igh Gene Assembly
    Eugene M Oltz; Fiscal Year: 2010
    ..Aberrant targeting of V(D)J recombination can produce chromosomal translocations involving proto-oncogenes. These translocations are initiating lesions in the vast majority of leukemias and lymphomas...
  57. The role of cMET in satellite cells during muscle regeneration
    MICAH TAUBE WEBSTER; Fiscal Year: 2013
    ..As deregulation of c-MET signaling is implicated in myriad tumors, this research may be relevant to multiple cancers. ..
  58. Cerebral Artery Alpha1 Adrenergic and PKC Regulatory Mechanisms
    Lawrence D Longo; Fiscal Year: 2013
    ..is that development significantly alters 1-AR-subtype- and specific PKC isozyme-mediated expression of proto-oncogenes and genes representing vascular smooth muscle "synthetic" and/or "proliferative" phenotypes, as compared to ..
  59. Inflammatory Proteases, Ubiquitin Proteasome System, and Myocyte Death
    Abdelkarim Sabri; Fiscal Year: 2012
    ....
  60. Analysis of the Human c-myc Gene Replication Origin
    Michael Leffak; Fiscal Year: 2012
    ..Thus, our studies are likely to provide fundamental new insight into the mechanisms of DNA replication, the origins of genetic diseases, and new models for disease treatment. ..
  61. Autophagy in epidermal melanocyte: a protective or a destructive role?
    Vijayasaradhi Setaluri; Fiscal Year: 2013
    ....
  62. Energy Restrction and Mammary Cancer
    Henry J Thompson; Fiscal Year: 2013
    ....
  63. Development of sd-rxRNAs as Therapy for Retinoblastoma and Other Malignancies
    Pamela Pavco; Fiscal Year: 2012
    ..Tumor suppressor mutations account for ~80% of all cancer mutations, but unlike activating mutations in oncogenes, cannot be targeted by drugs that inhibit a mutant gene product...
  64. REGULATION OF P53 IN CERVICAL CARCINOMA BY HEAT/HYPOXIA
    Amato Giaccia; Fiscal Year: 1999
    ..and other have demonstrated an increase in chromosome instability either by the deregulated expression of proto-oncogenes such as ras that accelerates cell proliferation or through the loss of negative growth regulators such as p53 ..
  65. SALIVARY GLAND TRANSGENIC MOUSE MODEL
    ELISA DURBAN; Fiscal Year: 1990
    ..The long range goal of the applicant's laboratory is to establish the mechanisms whereby activated oncogenes with different functions may interfere with normal and abnormal salivary epithelial cell transitions...
  66. PROSTATE CANCER GENE THERAPY WITH RECOMBINANT VACCINES
    Martin Sanda; Fiscal Year: 1999
    DESCRIPTION: (Applicant's Abstract) The hypothesis of the proposed studies is that modulation of prostatic oncogenes by androgen deprivation can augment the efficacy of oncogene-specific recombinant viral vaccine therapy of prostate ..
  67. ANALYSIS OF CELLULAR ONCOGENES IN VIRUS-INDUCED TUMORS
    David Steffen; Fiscal Year: 1992
    ..The plan focuses on a family of genes which are targets for cancer causing mutations referred to as the proto-oncogenes. Using thymic lymphomas induced in rats by Moloney murine leukemia virus (MoMLV), new oncogenes will be ..
  68. SKI PROTO-ONCOGENE FAMILY IN EARLY DEVELOPMENT
    Sonia Pearson White; Fiscal Year: 1992
    ..or skeletal myogenic pathways; 4) characterize potential interactions between ski and MyoD1 family proteins, oncogenes and growth factors, including the ability of each to induce the expression of others and the ability of ski to ..
  69. TRANSFORMING GENES IN INHALATION CARCINOGENESIS
    Seymour Garte; Fiscal Year: 1991
    This application seeks to continue the progress made in analysis of oncogenes activated in a well-defined experimental tumor model system...
  70. NCI CLINICAL INVESTIGATOR AWARD
    Kemp Cease; Fiscal Year: 1990
    ..genome encodes a recombinant gag-abl protein with tyrosine kinase activity and belonging to the src family of oncogenes. In human chronic myelogenous leukemia (CML) an analagous recombinant bcr-abl protein is expressed resulting ..
  71. ESTROGEN CONTROL OF UTERINE CELL PROLIFERATION
    Sohaib Khan; Fiscal Year: 1993
    ..estrogens elicit their effects in causing uterine cell proliferation through the increased expression of proto-oncogenes. To elucidate the role of oncogene expression in steroid-induced uterine responses, the following specific aims ..